Alex Herrera
Chief, Division of Lymphoma
City of Hope Comprehensive Cancer Center · Duarte, United States
Leads lymphoma at City of Hope. PI of 40+ clinical trials for Hodgkin and non-Hodgkin lymphomas. Co-chair of NCI Lymphoma Steering Committee.
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).
Clinical cancer research : an official journal of the American Association for Cancer Research · Mar 2, 2026
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.
Leukemia · Jan 1, 2026
Clinical characteristics, treatment patterns, and survival in mantle cell lymphoma: a real-world cohort.
Frontiers in oncology · Jan 1, 2026
Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Leukemia & lymphoma · Oct 31, 2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.
Blood advances · Oct 28, 2025
Multifaceted cfDNA profiling in mantle cell lymphoma.
Blood advances · Sep 9, 2025
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.
The Journal of clinical investigation · Mar 17, 2025
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.
The Journal of clinical investigation · May 15, 2024